Connection

Co-Authors

This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and ASHISH KAMAT.
Connection Strength

0.296
  1. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024 Sep; 134(3):449-458.
    View in: PubMed
    Score: 0.060
  2. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.058
  3. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.
    View in: PubMed
    Score: 0.051
  4. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
    View in: PubMed
    Score: 0.046
  5. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71.
    View in: PubMed
    Score: 0.023
  6. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34.
    View in: PubMed
    Score: 0.021
  7. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):14987-92.
    View in: PubMed
    Score: 0.020
  8. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol. 2005 Dec; 174(6):2186-90.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.